Dr. Wei, President of Chime Biologics, is a healthcare and life sciences executive with over two decades of global experience. Prior to joining Chime Biologics, Dr. Wei has led the incubation and investments activities into multiple well-known biotech companies, including Zai Lab, I-Mab, XW Labs, CMAB and JHL Biotech.
Dr. Wei was a founding partner of Pivotal Capital and I-Bridge Capital, and a partner of KPCB China Fund. Before joining KPCB, Dr. Wei was Senior Vice President and Head of Business Development at Hutchison Medipharma, where he was responsible for establishing global partnerships with several multinational pharmaceutical companies, including AstraZeneca, Johnson & Johnson, Lilly etc.
Dr. Wei graduated from North Carolina State University with PhD in biochemistry. He also holds an MBA with honors from the Darden Business School, University of Virginia, and a Bachelor’s degree in Biology from Wuhan University.
Dr. Pang has over 20 years of broad experience with strong portfolio of success leading the strategic development of drug development and CDMO management in the pharmaceutical and biotechnology industries.
Before joining, Dr. Pang served as SVP of ChemPartner and CEO of ChemPartner Biologics. Dr. Pang has started working in Chime BIologics since 2014 and held the General Manager position between 2018 to 2021. Dr. Pang held several key technical, regulatory and management positions in various pharmaceutical and biotechnology positions in Vancouver and Hong Kong.
Dr. Pang holds a Ph.D. in chemical engineering from the University of British Columbia, Canada. He then joined the Nobel Laureate Michael Smith Laboratories Centre for Blood Research at the University of British Columbia as a Postdoctoral Fellow.
Dr. Zheng has 25 years of broad experience in biotech industry to develop therapeutic proteins, antibody drugs and vaccines in USA and China. His expertise spans from process development, technology transfer to cGMP production. He is a CMC leader with experience to develop both biosimilar and innovator drugs, and has brought multiple biologic products to market.
Previously Dr. Zheng is the co-founder and VP of DZM Biotech and VP of Jecho Biopharma. Before returning back to China 10 years ago, he held several technical and management positions as principal scientist and project manager in MedImmune, Wyeth, Pfizer with increased responsibilities.
Dr. Zheng received his bachelor degree in chemistry from Beijing Normal University, Ph.D. in chemistry from Nankai University, and did his postdoctoral training in Department of Chemistry, Aarhus University, Denmark and Department of Chemistry and Biochemistry, University of Delaware, USA.
Mr. Chen has over 20 years’ experience in biomedical research, marketing, business, project management, capital raising, corporate senior management and operations. Before joining Chime Biologics, he served as General Manager, Senior Vice President and Marketing Director of Wuhan Optics Valley New Drug Incubation Public Service Platform Co., LTD., and also worked in Vital Pharmaceutical as Marketing Manager, R&D supervisor and other management positions. He is familiar with company operation and capital operation, and has rich experience in team building and business cooperation negotiation.
Mr. Chen obtained a Master degree in Microbiology and Biochemistry from Wuhan University.
Mr. CHANG POH HOON has extensive experiences in Quality-oriented with experience in pharmaceutical quality systems, GMP quality audits, validation, GMP production, engineering management and materials management. He is familiar with GMP expectations of EU, US, China and also as defined by PIC/S. Prior to Chime, he held very important positions at Novartis, Pfizer, MSD, etc.
Thomas has over 35 years of manufacturing experience, including 25 years in biotechnology industry, in the production of therapeutic proteins, antibodies, and vaccines in the United States. He is a manufacturing leader with experience in the production of several commercial blockbuster biologics and numerous clinical therapeutics. Previously Thomas held leadership, technical and commercial positions in Amgen Rhode Island, Regeneron Pharmaceuticals and Bio-Rad Laboratories.
Thomas received his bachelor’s degree in Biological Sciences from the State University of New York at Albany.
Berkan brings an impressive and diverse resume, including over 10 years of experience in the biopharmaceutical industry and solid connections to global leaders in the bio-pharmaceutical sector.
Before joining Chime Biologics he worked for GenScript Biotech and ProBioGen AG. Both are global leading CDMOs and Berkan has been involved in the processes which provides end-to-end solutions from discovery to commercialization of Biologics. His experience is a welcomed addition to our team and will jump start Chime Biologics Europe initiatives.
Berkan studied bioprocess engineering and medical biotechnology at the Berlin Technical University of Applied Sciences, Hamburg University of Technology and the Imperial College London.
Walter Tian is an industry veteran with well over 30 years of track record in life science and biopharmaceutical CRDMO industries. In his earlier career he worked in sales and marketing capacity for some well known US and international life science companies including PerkimElmer, Qiagen and OriGene. Over the last 12 years, he held key corporate marketing and business development positions in both CRO companies (DNA2.0/Atum, LakePharma) and CDMO companies (LakePharma and Curia). His impressive network in drug research and development in North America is critical to Chime’s global mission.
Walter received his bachelor degree in medicine at Xi’an Medical School and MS degree in immunology at Beijing Medical University. He also has an MBA certificate from Northeastern University in Boston, MA.
Mr. Huang is also Managing Partner of Kleiner Perkins Caufield & Byers China. He joined the firm in 2011 and focuses on the firm’s life sciences practice. His main investment interests are innovation around China’s growing healthcare markets and helping entrepreneurs build companies. Mr. Huang has made more than 15 investments in China since 2007.
Prior to that, Mr. Huang was a Managing Partner at Vivo Ventures, a Venture Capital firm specializing in life sciences investments. While at Vivo, Mr. Huang led numerous investments in China. Before joining Vivo in 2007, Mr. Huang was President of Anesiva, a biopharmaceutical company focused on pain-management treatments. During his 20-year career in the pharmaceutical and biotech industry, he also held senior roles in business development, sales, marketing and R&D with Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. (acquired by Johnson & Johnson).
Mr. Huang is Chairman of Board at Kindstar Global, Eden Biologics and XW Laboratory and Director at GenScript, ChiralQuest, Zenesis, CVie Therapeutics, CASI and Omni Pharmaceuticals.
Mr. Huang received an M.B.A. from the Stanford Graduate School of Business and a B.S. degree in Chemical Engineering from the University of California, Berkeley.
VMS Group of Companies is a leading multi-strategies financial services group providing individual, corporate and institutional investors with investment solutions as well as securities brokerage and corporate finance advisory services. The Group’s main operating subsidiaries, VMS Securities Ltd and VMS Asset Management Ltd, are licensed by the Securities and Futures Commission to conduct respectively (i) dealing in securities and advising on corporate finance, and (ii) advising on securities and asset management regulated activities. VMS makes and advises on investments in both private and listed equities, special and distress situations, takeovers, debts and loans.
Mr. Chong is also the Executive Chairman and CEO of Auto Italia Holdings Ltd (a company listed on the Main Board (stock code: 00720)) since 2013.
Mr. Chong has been appointed as an Executive Director, the Chairman of the Board, the Chairman of the Investment Committee and member of each of Nomination Committee and the Remuneration Committee of Newton Resources Ltd (a company listed on the Main Board (stock code: 01231)) since 2018.
Mr. Chong holds a Bachelor Degree of Commerce from the University of Toronto, Canada and a Master Degree of Science in Investment Management from the Hong Kong University of Science and Technology, Hong Kong. He obtained the qualification as a Chartered Financial Analyst from the Association for Investment Management and Research (now known as the CFA Institute) in 1997.
Since 2014 Mr. Funk has transformed Lonza Pharma & Biotech by consolidating its operations all over the world and bringing its quality and operational standard to a world class level. Under his leadership Lonza Group has enjoyed seven consecutive years of rapid business growth. As a world renowned business leader, Mr. Funk has accumulated vast industry experience and deep business connections across the whole healthcare sector in Europe, North America and Far East.
Mr. Funk obtained a Master of Law and Diplomacy from Tuft University in USA and a Master of Law from University of Geneva in Switzerland.
Mr. Ng established the healthcare investment practice of VMS Group in 2017 and has completed multiple growth-stage investments and private equity investments across the verticals of therapeutics, diagnostics, medical devices, and CXOs. He currently sits on the board of multiple healthcare companies. Prior to joining VMS Group, Mr. Ng had been the Lead Analyst for the China Healthcare Equity Research at Barclays Capital.
Mr. Ng obtained a Bachelor of Science degree and a Master of Engineering degree from Cornell University and an MBA degree from INSEAD.
